Search for Noninvasive Markers of "Graft Injury" in Pediatric and Adult Patients With Congenital Heart Disease Undergoing Cardiac Transplantation

Recruiting now · Not applicable

Conditions studied: Congenital Heart Disease (CHD), Heart Transplant Patients, Adult Congenital Heart Disease, Pediatric Congenital Heart Disease

In brief

This clinical tissue-based, drug-free, single-center, longitudinal study aims to validate a new diagnostic method, namely, to evaluate whether plasma levels of circulating donor free DNA in the recipient's blood (Dd-cfDNA: donor-derived cell free DNA), in patients undergoing orthotopic heart transplantation, can be predictive of the presence of acute myocardial rejection with the same sensitivity as immunohistochemical analysis on endomyocardial biopsy specimen, the current gold standard for the diagnosis of acute cell-mediated myocardial rejection, in a population consisting of pediatric patients and adult patients with congenital heart disease undergoing orthotopic heart transplantation.

Key facts

Study ID
NCT06784440
Run by
IRCCS Azienda Ospedaliero-Universitaria di Bologna
People needed
20
Starts
2023-03-08
Expected to finish
2026-03-07
Last updated by the study team
2025-01-20

Who can join

Age: any, up to 44. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.